ABSTRACT by sending out questionnaires to 72 Japanese pharmaceutical companies. The survey yielded data for 108 -tive studies in rodents and non-rodents, respectively. As a result of the analysis, 83% of studies in rodents and 80% in non-rodents showed EFD effects in the DRF studies. When focusing on teratogenicity, 91% of studies in rodents and 100% in non-rodents were judged "positive" in the DRF studies when all EFD toxicities were used as markers. When the effects of both the rodent and non-rodent studies were evaluated together, the combination predictive value in the DRF studies was 96% for EFD toxicants and 100% for compounds for which full examinations (external, visceral and skeletal examination) were conducted in both rodent and non-rodent DRF studies. When the results were judged by including or excluding skelethe results of this survey showed that a pair of the DRF studies in the rodents and non-rodents is useful to increase the predictivity of DRF studies. In addition the inclusion of observations such as fetal survival, -tive studies.
INTRODUCTION
In drug development, the need to avoid the risk to the embryo or fetus is imperative when including women of childbearing potential (WOCBP) in clinical trials. To achieve this objective, use of highly effective methods of birth control or pregnancy test before and during the clinical study is essential. In addition to taking precautions to prevent pregnancy during clinical trials, conducting embryo-fetal development (EFD) studies can be useful to characterize the inherent risk of a compound so as to be able to better inform of the risks if an exposure during pregnancy occurs, and to make an assessment of the suitability of the compound as a development candidate. The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) has published ICH-M3 guideline (Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals) which addresses the principles for the development of non-clinical strategies and on the timing of toxicity studies in relation to the conduct of clinical trials. In M3 (R1) guideline, there had been regional differences in the timing of the EFD toxicity studies to support the inclusion of WOCBP in clinical trials, that is, EFD studies should be completed prior to the inclusion of WOCBP in any type of clinical trial in Japan and the EU, whereas, in the US, WOCBP may be included in early, carefully monitored studies without EFD studies (ICH harmonized tripartite guideline, 2000) .
EFD studies are time-consuming and require technical expertise and large number of animals. The methods and endpoints for EFD studies are stated in the ICH-S5 (R2) guideline (Detection of toxicity to reproduction for medicinal products & toxicity to male fertility). In accordbe conducted with about 20 dams per group in 2 species (rodents and non-rodents) in compliance with good laboratory practice (GLP) . From the point of view of appropriate animal usage in research, studies should be conducted at a time that is necessary to support clinical safety. However, one could question the need for such studies early in clinical trials where pregnancy is extremely unlikely while on clinical study. In contrast, the pregnancy rate in the clinical studies might be increased as clinical trials get longer and larger and less daily oversight is likely to occur. Considering these points together the balance between the scales of the clinical studies (duration of the treatment and number of the volunteers) and the sizes of the non-clinical studies are most important.
Generally, many pharmaceutical companies conduct the definitive EFD studies. The DRF studies are conducted in the early stages of the drug development on a small scale and with limited endpoints. The results from the DRF studies have not been utilized for the evaluation of EFD toxicities, since the purpose was to set the dose pregnant animals. The DRF studies may vary between the companies and/or compounds because DRF studies are not regulated by the guideline. Moreover, the DRF methods, endpoints and/or predictivity for EFD effects are unknown because the details of the DRF studies have not been published.
To explore the possibility of using the information from DRF studies, we conducted a survey about the EFD studies done in the pharmaceutical companies which were members of the Japan Pharmaceutical Manufactures Association (JPMA) in order to investigate the predictivity of the DRF studies.
MATERIALS AND METHODS
Questionnaires were distributed to 72 member pharma--ducted during April 6-20, 2007 and the follow-up survey was conducted during October 16, 2007 -January 15, 2008 .
The questionnaires were provided by the ICH M3 expert working group to obtain a set of summaries of the using a formatted answer sheet including questions on the study design (fetal examination items and the number of the litters per group) and the maternal/fetal effects (effective dose levels and the types of fetal effects) (Fig. 1) . The data set was sought for compounds which met all the following criteria: (1) an EFD study had been conducted studies had been performed, and (3) any EFD toxicities were observed in the definitive studies. The "any EFD death, decreased fetal body weight, fetal malformation or variation (external, visceral and/or skeletal) and/or fetal limited. The data sets, consisting of data from the prelimifor 108 studies for rodents (5 in mice and 103 in rats) and 85 studies for non-rodents (rabbits). The net number of the analyzed compounds was 136 since 57 studies among 193 studies (108 in rodents and 85 in non-rodents) were obtained from the same compounds. The numbers of the compounds for each company are shown in Table 1 .
Persons in each company who were knowledgeable about reproductive and developmental toxicity were requested to respond. The answer sheets were returned to the JPMA staff who replaced company names with code numbers to blind the analysis that was then conducted by the authors. The follow-up survey for the compounds in which teratogenic effects were not detected in the DRF studies was done to clarify the details using a interview with each company.
The data were analyzed using the identical code assigned by the allocated company number, compound number and test species. The end points of the analysis were as follows; (1) study designs of the preliminary or DRF studies, (2) predictive value of the preliminary or DRF study to detect any of the embryo-fetal toxicities -tive value of the preliminary or DRF studies to detect any of the embryo-fetal toxicities by the combination of the examined in the preliminary or DRF studies on the predictive value of EFD toxicities. The complete dataset and analysis was also reviewed by the ICH M3 working group.
RESULTS

Study design of the preliminary or DRF studies
The methods used in the DRF studies varied between the studies. In almost all the studies, caesarian section was conducted with examination for embryo-fetal death, and fetal body weights were measured. However, the number of dams per group and fetal examination items such as external, visceral and/or skeletal examinations were different between the studies. Regarding the number of the group in rodents. The range of the dam numbers per group out of 85 studies used six dams per group and the range fetal morphological examinations, in about a half of the examinations done in the DRF studies. In the remaining half of the studies (51%, 55 out of 108 studies in rodents -inations (external, visceral and skeletal) in the DRF studies were done (Fig. 3 ).
pounds showed maternal deaths in the DRF studies, compared with 6 out of 108 compounds in the definitive studies in rodents. In non-rodent studies, 27 out of 85 compounds showed maternal deaths in the DRF studies, studies.
Predictivity of the preliminary or DRF studies to
As described above, this analysis was conducted with EFD toxicities including embryo-fetal death, decreased Number of compounds for which NEITHER the exploratory/RF study NOR the definitive study had treatment-related fetal findings and/or malformations: Number of compounds for which treatment-related fetal findings and/or malformations were present BOTH in the definitive study AND in the exploratory/RF study: Number of compounds for which treatment-related fetal findings and/or malformations were present in the definitive study but NOT the exploratory/RF study: Number of compounds for which treatment-related fetal findings and/or malformations were present in the exploratory/RF study but NOT the definitive study: Please provide the number of compounds in each of the following 4 categories either for studies conducted over the past 10 years or for the last 50 compounds, whichever is lower.
No Y: Contraindication in pregnancy fetal body weight, fetal malformation or variation (exter--cation were detected in the DRF studies, the studies were regarded as "positive". The predictive value was calculated by the following formula: (the number of "positive" studies in the DRF studies/ the number of the analyzed studies)*100.
In the results of the analysis, the predictive values of DRF studies for EFD toxicities were 83% (90 out of 108 studies) and 80% (68 out of 85 studies) in rodents and
Predictivity of the preliminary or DRF studies studies
Focusing on the fetal malformations, the same analyses were conducted for the studies in which any malformations (external, visceral and/or skeletal) were detected in -studies) and 57% (12 out of 21studies) by the DRF studies in rodents and non-rodents, respectively (Fig. 5) .
Another analysis was conducted in which the studies were regarded as "positive" when any EFD toxicity including embryo-fetal death, decreased fetal body The studies in rats and mouse were conducted with the same compound.
Vol. 35 No. 1 weight, fetal malformation or variation (external, vis--tion was detected in the DRF studies. In the results of the (21 out of 21 studies) in non-rodents were judged "positive" (Fig. 6) .
Only 3 studies in rodents exhibited no EFD toxicity in the DRF studies because of a low incidence of malformations (2 studies; they had no effects on fetal death or lack of the appropriate examination (1 study; visceral and skeletal examinations were not conducted and only visin the DRF studies.
Predictivity of the preliminary or DRF studies to detect any EFD toxicity or fetal "malformation" the rodent and non-rodent studies
When the effects of both the rodent and non-rodent studies were evaluated together, 56 compounds had both rodent and non-rodent data sets, that is, these 56 compounds showed EFD toxicity in both rodents and nonFirst, the analysis was conducted with "EFD toxicants", in which any EFD toxicity including embryofetal death, decreased fetal body weight, fetal malformation or variation (external, visceral and/or skeletal) and/or retardation of fetal ossification were observed in both -tive value was calculated by the following formula: (the number of "positive" compounds in the DRF studies/ the number of the analyzed compounds)*100 In this formu- la, "positive" meant any EFD effects were detected in both or either rodent and non-rodent preliminary or DRF studies. The combination predictive value for "EFD toxiNext, focusing on the fetal malformations, the same analyses were conducted for the "teratogens" in which any malformations (external, visceral and/or skeletal) rodents or non-rodents. The combination predictive value for the teratogens which had both rodent and non-rodent data sets was 100% (23 out of 23 compounds) ( Table 2) .
predictivity of the preliminary or DRF studies
To analyze the influence of the items examined, the predictive value was calculated assuming that fetal skeletal and visceral examinations were not conducted, that is, the EFD effects were evaluated only by embryo-fetal death, decreased fetal body weight and/or external examinations.
examinations (external, visceral and skeletal examination) were conducted in both rodent and non-rodent DRF studies. The analysis was conducted in the same manner as the combination analysis described above. The combination with full examination and without visceral and skeletal examinations results, respectively (Table 3) . That is, the EFD effects could not be detected in 3 compounds without visceral and skeletal examinations results; two compounds showed only skeletal variation as a fetal effect in the DRF studies in rodents, and one compound showed only skeletal retardation as a fetal effect in the DRF studies in non-rodents.
Focusing on the fetal malformations, the combination predictive value was 95% (20 out of 21 compounds) for the "teratogens" in both situations (Table 3) . Differences in the predictivity between the values including and excluding fetal visceral or skeletal examinations results were not evident.
In addition, another analysis was conducted to esti--pounds for which full observations in the DRF studies --nal observation, fetal death and low fetal body weight are used as markers, only 1 of 17 compounds could not be a : Any EFD toxic findings including embryo-fetal death, decreased fetal body weight, fetal malformation or variation (external, Positive: Any EFD effects were detected in both or either rodent and non-rodent preliminary or DRF studies. Positive: Any EFD effects were detected in both or either rodent and non-rodent preliminary or DRF studies. c : Predictivity (%) = The number of "positive" compounds in the preliminary or DRF studies/ the number of the analyzed compounds*100. d : Including the one compound which included two rodent data sets ( rats and mice) and a non-rodent data set.
detected the EFD toxicity in the DRF study in rodents. The compound showed no effects on skeletal and visceral observations so it would not be positive even if skeletal and visceral examinations were performed. In nonrodents, no compound (0 of 10 compounds) was missed.
DISCUSSION
In this survey among member companies of the JPMA, we assessed the design of the DRF study in the rodents and non-rodents and their predictivity by comparing with -ed to GLP.
As for the study design in the DRF studies, six dams per group were most common and about a half of the studies were conducted with only external examination for fetal morphology in both the rodents and non-rodents. These results may indicate that the DRF studies are sim--ies rather to detect the detailed information about the EFD toxicity.
The number of the DRF studies showing maternal rodents and non-rodents. These results may suggest that the maximum dose tested was relatively high in the DRF -bly because the DRF studies are conducted with limited information.
Under these study conditions, the predictive values of -itive studies was more than 80% in both rodent and nonrodent studies. There was no obvious difference between species for the predictivity.
For the teratogens which showed malformations in the in which the malformations were detected was only about 50% in both the rodents and non-rodents. This may indido not preclude teratogenic findings in the definitive dose levels are used. However, the predictive value for -er (91% in rodents and 100% in non-rodents) when any developmental effects including fetal death and/or low fetal body weight in the DRF studies were used as potential predictive markers for adverse fetal effects. Therefore, the evaluation including the endpoints of fetal body weight and embryo-fetal death was considered to be important to evaluate potential teratogenicity. There were 3 compounds which showed no EFD effects in the DRF The DRF studies for two compounds were conducted in the small scale as usual and the incidences of malformastudy didn't conduct the full observation, thus, the DRF studies were likely underpowered to detect the effects.
The combination analysis with rodent and non-rodent results showed that the predictive values for the combination was higher than that for each result by a complementary effect and the values were 96% for "EFD toxicants" and 100% for teratogens. This result suggests that the predictivity becomes very high if a compound is studied in the DRF in 2 species. revealed that the differences in the predictive value between the limited examinations (i.e., external observateratogens and EFD toxicants. Moreover, there were no compounds which were detected only by visceral examination. It is well known that many EFD toxicants represent a continuum of increasing toxicity, with low doses producing growth retardation (low fetal body weight) and increasing doses producing malformations and then lethality (Rogers and Kavlock, 2007) . Consequently, it is reasonable that the end points of fetal body weight and embryo-fetal death are useful markers to detect the embryo-fetal toxicants.
In conclusion, the results of this survey showed that a pair of the DRF studies in the rodent and non-rodent species are considered to be able to provide critical informa--itive study if adequate dose levels, numbers of dams, appropriate observation items such as fetal survival, body weight and external examination are used. It should be noted that fetal lethality and decreased fetal body weights should be regarded not only as the signal of the developmental retardation but also as a signal that may herald teratogenic potential.
Limitation of interpretation
There may be limitations to the generalization of the interpretation of this analysis because: 1) the numbers of the compounds and the companies are limited; 2) the interpretation was based on the hypothesis that there is no difference in methodology between the DRF study and examination items; however, there could be unknown differences such as toxicokinetics in the dams. However, such differences are considered small because the companies have used these data to make their internal decisions on dose selection for subsequent studies. On the other hand, this survey focused on the sensitivity of the DRF been elucidated through this survey. The proposed setting of supporting early clinical development, however, sensitivity is considered to be more important for the purpose concluded from the above analysis that the DRF studies strategies to minimize pregnancy rates are incorporated into the clinical design.
